Mimedx Group Inc Stock Price, News & Analysis

MIMEDX (NASDAQ: MDXG) announced its participation in the upcoming BofA Securities 2025 Healthcare Conference in Las Vegas, NV. The Company's senior management team is scheduled to present on Tuesday, May 13, 2025, at 5:15 p.m. PDT. Interested investors who wish to meet with MIMEDX's senior management during the conference should contact their Bank of America representative to arrange meetings.

MIMEDX (NASDAQ: MDXG) has published significant health economics data in the Journal of Drugs in Dermatology regarding their EPIFIX® placental allograft product for wound reconstruction after Mohs surgery. The study of 429 Mohs patients demonstrated superior outcomes compared to traditional methods. Key findings include: - 97.2% of EPIFIX patients experienced no complications vs 78.7% with traditional methods - Average length of care reduced to 33.3 days vs 48.3 days for autologous tissue repairs - Substantial cost savings achieved through fewer complications and reduced additional procedures The data is particularly significant as Mohs surgery is performed over 850,000 times annually in the U.S. for treating common skin cancers. This research supports EPIFIX as an effective alternative to traditional surgical methods, particularly beneficial for high-risk surgeries and hospital systems focused on health economics.

MIMEDX reported solid Q1 2025 financial results with net sales of $88 million, marking a 4% year-over-year growth. The company achieved GAAP net income of $7 million and earnings per share of $0.05.

Key highlights include:

• Surgical products showed strong 16% growth, driven by AMNIOEFFECT and HELIOGEN
• Wound products experienced a slight 2% decline
• Gross margin was 81%, down from 85% in the prior year
• Adjusted EBITDA reached $17 million, representing 20% of net sales
• Cash position of $106 million as of March 31, 2025

CEO Joseph H. Capper expressed disappointment over LCD delays but announced plans to bridge gaps with new products like CELERA. The company reaffirmed its 2025 outlook, expecting high single-digit net sales growth and Adjusted EBITDA margin above 20%. Long-term goals include achieving low double-digit annual net sales growth.

MIMEDX Group (Nasdaq: MDXG) has announced its upcoming first quarter 2025 financial results release and conference call schedule. The company will disclose its operating and financial results for Q1 2025 (ended March 31) after market close on Wednesday, April 30, 2025.

The senior management team will host a webcast and conference call at 4:30 p.m. Eastern Time on the same day. Investors can access the call through dedicated U.S. (877-407-6184) and International (201-389-0877) lines using Conference ID 13752696. A replay of the webcast will be available on www.mimedx.com for approximately 30 days following the event.

MIMEDX (NASDAQ: MDXG) has announced its participation in three major industry conferences to showcase its latest scientific and clinical data for Advanced Wound Care and Surgical Solutions. The company will be present at:

1. MedStar Georgetown University Hospital's Diabetic Limb Salvage Conference (April 10-12, 2025) featuring a sponsored lunch symposium on limb salvage strategies

2. Symposium on Advanced Wound Care (SAWC) Spring 2025 (April 30-May 4, 2025) including a sponsored lunch symposium on wound healing

3. Digestive Disease Week (DDW) 2025 (May 3-6, 2025) featuring an oral presentation on hospital readmissions and anastamotic leaks in colorectal surgery

CEO Joseph H. Capper emphasized the company's commitment to innovation and expanding their clinical evidence base, particularly highlighting their expansion into gastrointestinal surgery applications.

MIMEDX (Nasdaq: MDXG) has announced its participation in the TD Cowen 45th Annual Health Care Conference, scheduled for March 3-5, 2025, at the Boston Marriott Copley Place. The company's senior management will deliver a presentation on Tuesday, March 4, 2025, at 11:10 AM ET.

The conference will feature presentations, fireside chats, and panel discussions focused on various aspects of the healthcare industry, moderated by TD Cowen research team members. Institutional investors can arrange meetings with MIMEDX senior management through their TD Cowen representatives.

A live webcast of the presentation will be accessible through the Events page in the Investors section of MIMEDX's website, with a replay available after the event.

MIMEDX (NASDAQ: MDXG) reported strong financial results for Q4 and full year 2024. Fourth quarter net sales grew 7% year-over-year to $93 million, while full-year net sales increased 9% to $349 million.

Q4 highlights include GAAP net income of $7 million ($0.05 per share) and Adjusted EBITDA of $20 million (21% of net sales). Gross margin was 82% for Q4 2024, with adjusted gross margin at 84%. The company maintained strong cash position with $104 million in cash and cash equivalents as of December 31, 2024.

Looking ahead to 2025, MIMEDX expects high single-digit net sales growth and Adjusted EBITDA margin above 20%. Long-term outlook projects low double-digit annual net sales growth with continued Adjusted EBITDA margin exceeding 20%.

MIMEDX Group (Nasdaq: MDXG) has announced its upcoming fourth quarter and full year 2024 financial results release, scheduled for after market close on Wednesday, February 26, 2025. The company's senior management team will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results.

Investors can access the conference call through a webcast or by phone, with separate dial-in numbers provided for U.S. (877-407-6184) and international investors (201-389-0877). A replay of the webcast will be available on the MIMEDX website for approximately 30 days following the event.

MIMEDX (NASDAQ: MDXG) has filed a patent infringement lawsuit against Surgenex in the U.S. District Court for the District of Arizona. The lawsuit alleges that several of Surgenex's placental allograft products infringe on MIMEDX's patents, seeking permanent injunctive relief and monetary damages. This is the second lawsuit against Surgenex, following earlier litigation regarding alleged corporate raiding and unfair competitive practices. MIMEDX, holding over 70 patents in the placental allograft category, plans to expand its investigation into potential patent infringements by other competitors amid the increasing number of skin substitutes entering the market.